

Supplementary Information

Article title: Intranasal 5-MeO-DMT concomitant with SSRI for treatment-resistant depression: a proof-of-concept trial

Mathieu Seynaeve (MD)^{1,2*}, Robert R. Conley (MD, PhD)², Fiona Dunbar (MD)³, Anna O. Ermakova (PhD)², Chandni Hindocha (PhD)², Mimi Pierce (MD)² and Claire Roberts (PhD)²

¹ Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

² Beckley Psytech Ltd, Oxford, UK.

³ Beckley Psytech Ltd, Consultant, Toronto, Canada.

Number of words in main manuscript: 1109

Number of tables: 2

Number of figures: 1

* Corresponding author:

Mathieu Seynaeve

Address: 16 De Crespigny Park, London SE5 8AF, United Kingdom

Contact telephone: +447400657116

Email: Mathieu.Seynaeve@kcl.ac.uk

Supplementary Table 1. Participant demographics

Variable	BPL-003 10 mg (N=6)	BPL-003 12 mg (N=6)
Gender (n [%])		
Male	1 (16.7)	4 (66.7)
Female	5 (83.3)	2 (33.3)
Age (years)		
Mean (SD)	43.3 (13.03)	36.2 (13.14)
Range	27–56	22–58
Race (n [%])		
White	5 (83.3)	6 (100)
Other	1 (16.7)	0 (0)
Ethnicity (n [%])		
Not Hispanic or Latino	6 (100.0)	6 (100.0)
Time since MDD diagnosis (months)		
Mean (SD)	201.3 (123.4)	182.7 (119.7)
Range	53–373	52–341
Duration of SSRI treatment in current episode		
Mean (SD)	50.6 (62.4)	18.5 (18.6)
Range	5–170	5–54
SSRI		
Sertraline	4	4
Citalopram	2	2
Number of failed AD in current episode		
Mean (SD)	2.8 (0.75)	3.0 (1.10)
Range	2–4	2–5
Duration of current episode (months)		
Mean (SD)	227.8 (176.1)	123.7 (117.1)
Range	65–496	20–341

Abbreviations: SD: Standard deviation; MDD: Major depressive disorder; SSRI: Selective serotonin reuptake inhibitor; AD: Antidepressant